Analgesic efficacy of Tenoxicam,Nalbuphine and Magnesium sulphate as adjuvant to intraarticular Levobupivacaine in knee art
Not Applicable
Not yet recruiting
- Conditions
- Musculoskeletal DiseasesSurgeryknee arthroscopy
- Registration Number
- PACTR201704002155170
- Lead Sponsor
- Hatem Elmoutaz
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Male
- Target Recruitment
- 90
Inclusion Criteria
Male patients
-Age 18-50 years
Exclusion Criteria
Patients will be excluded from the study if they had sickle cell disease, peripheral vascular disease, history of DVT, poorly controlled hypertension, history of allergy to the studied drug, treatment for chronic pain alcohol and substance addiction chronic use of NSAID, opiates
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Tenoxicam's analgesic synergy with Levobupivacaine in knee arthroscopy?
How does Nalbuphine compare to other opioid adjuvants in post-arthroscopic pain management?
Are there specific biomarkers that predict enhanced analgesia with Magnesium sulphate in musculoskeletal surgery?
What adverse event profiles differentiate Tenoxicam, Nalbuphine, and Magnesium sulphate as Levobupivacaine adjuvants?
How do COX-2 inhibitors like Tenoxicam complement local anesthetics in orthopedic procedures?